ASCO 2026: Olverembatinib Data & Gastric Cancer Trial Updates

Key Takeaways

• Ascentage Pharma will present data on olverembatinib (HQP1351) in leukemia and SDH-deficient tumors at the ASCO 2026 Annual Meeting.
• Ono Pharma is set to share Phase 2 trial results for ONO-4578 combined with nivolumab and chemotherapy as a first-line treatment for HER2-negative gastric cancer.
• A presentation will cover the Phase 3 ATTRACTION-6 trial of nivolumab plus ipilimumab and chemotherapy as a first-line treatment for HER2-negative advanced/recurrent gastric/GEJ cancer.

The ASCO 2026 Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, will feature key presentations from Ascentage Pharma and Ono Pharma on novel cancer therapies. These presentations will cover advancements in leukemia treatment and gastric cancer management, offering insights into potential new treatment strategies.

The ASCO Annual Meeting is a significant event for the oncology community, bringing together researchers, clinicians, and industry professionals to discuss the latest advancements in cancer treatment and care. Presentations at this meeting often highlight pivotal clinical trial results that can shape future treatment paradigms.

Ascentage Pharma's Olverembatinib Presentations

Ascentage Pharma will present data on olverembatinib (HQP1351) across several hematologic malignancies and solid tumors. Key presentations include:

• Rapid Oral Presentation (Abstract 6513): Olverembatinib (HQP1351) combined with blinatumomab in lymphoid blast phase CML-LBP or Ph+ BCP-ALL.
• Rapid Oral Presentation (Abstract 6510): A presentation focusing on pediatric applications of olverembatinib (HQP1351), with Yizhuo Zhang, MD, from Sun Yat-sen University Cancer Center in Guangzhou, China, as the first author.
• Poster Presentation (Abstract TPS6608): Updated results in SDH-deficient tumors.

IntelligenceRegulatory Impact▾

EMA and MHRA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in Europe. Regulatory relevance reads medium for general. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.

Ono Pharma's Gastric Cancer Trial Updates

Ono Pharma will present updates from trials focusing on gastric cancer treatments:

• Oral Presentation (Abstract 4007): Results from a Phase 2 trial (ONO-4578-08) evaluating ONO-4578 combined with nivolumab and chemotherapy as a first-line treatment for HER2-negative advanced/recurrent gastric/GEJ cancer. The presenter will be Sung Hee Lim from Samsung Medical Center in Seoul, Republic of Korea.
• Oral Presentation (Abstract 4006): Data from the Phase 3 ATTRACTION-6 trial, which investigates nivolumab plus ipilimumab and chemotherapy as a first-line treatment for HER2-negative advanced/recurrent gastric/GEJ cancer. Do-Youn Oh from Seoul National University College of Medicine in Seoul, Republic of Korea, will present the findings.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.

ASCO 2026 Details

The ASCO 2026 Annual Meeting will be held from May 29 to June 2, 2026, at McCormick Place in Chicago, IL. The meeting will cover a wide range of topics, with a focus on hematologic malignancies and solid tumors.

Frequently Asked Questions

What is the focus of ASCO 2026? The ASCO 2026 Annual Meeting will focus on the latest advancements in the treatment of hematologic malignancies and solid tumors. What data will Ascentage Pharma present at ASCO 2026? Ascentage Pharma will present data on olverembatinib (HQP1351) in leukemia and SDH-deficient tumors, including rapid oral and poster presentations. What gastric cancer trials will Ono Pharma present at ASCO 2026? Ono Pharma will present results from a Phase 2 trial of ONO-4578 combined with nivolumab and chemotherapy, as well as data from the Phase 3 ATTRACTION-6 trial of nivolumab plus ipilimumab and chemotherapy. Where and when will ASCO 2026 take place? The ASCO 2026 Annual Meeting will be held from May 29 to June 2, 2026, at McCormick Place in Chicago, IL.

References

1. Global Clinical Trials with Local Expertise in 2026. World Pharma Today.
2. ISGD Clinical Trials Summit 2026 Abstract Information. The International Society of Glomerular Disease.
3. Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026. Ascentage Pharma Press Release.
4. IQVIA Global Trends in R&D 2026. IQVIA.
5. Vivli Data Sharing Platform. Vivli.
6. Ono Pharma Presentations at ASCO 2026. Ono Pharma.

Related coverage

• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates